Therapeutic cell engineering with surface-conjugated synthetic nanoparticles
10.1038/nm.2198
Crossref journal-article
Springer Science and Business Media LLC
Nature Medicine (297)
Bibliography

Stephan, M. T., Moon, J. J., Um, S. H., Bershteyn, A., & Irvine, D. J. (2010). Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nature Medicine, 16(9), 1035–1041.

Authors 5
  1. Matthias T Stephan (first)
  2. James J Moon (additional)
  3. Soong Ho Um (additional)
  4. Anna Bershteyn (additional)
  5. Darrell J Irvine (additional)
References 32 Referenced 641
  1. Fiorina, P., Shapiro, A.M., Ricordi, C. & Secchi, A. The clinical impact of islet transplantation. Am. J. Transplant. 8, 1990–1997 (2008). (10.1111/j.1600-6143.2008.02353.x) / Am. J. Transplant. by P Fiorina (2008)
  2. Alison, M.R., Islam, S. & Lim, S.M. Cell therapy for liver disease. Curr. Opin. Mol. Ther. 11, 364–374 (2009). / Curr. Opin. Mol. Ther. by MR Alison (2009)
  3. Alper, J. Geron gets green light for human trial of ES cell–derived product. Nat. Biotechnol. 27, 213–214 (2009). (10.1038/nbt0309-213a) / Nat. Biotechnol. by J Alper (2009)
  4. Dimos, J.T. et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons 321, 1218–1221 (2008).
  5. Morgan, R.A. et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126–129 (2006). (10.1126/science.1129003) / Science by RA Morgan (2006)
  6. Hunder, N.N. et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N. Engl. J. Med. 358, 2698–2703 (2008). (10.1056/NEJMoa0800251) / N. Engl. J. Med. by NN Hunder (2008)
  7. Mackinnon, S., Thomson, K., Verfuerth, S., Peggs, K. & Lowdell, M. Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells. Blood Cells Mol. Dis. 40, 63–67 (2008). (10.1016/j.bcmd.2007.07.003) / Blood Cells Mol. Dis. by S Mackinnon (2008)
  8. Zeng, R. et al. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J. Exp. Med. 201, 139–148 (2005). (10.1084/jem.20041057) / J. Exp. Med. by R Zeng (2005)
  9. Wallace, A. et al. Transforming growth factor-β receptor blockade augments the effectiveness of adoptive T cell therapy of established solid cancers. Clin. Cancer Res. 14, 3966–3974 (2008). (10.1158/1078-0432.CCR-08-0356) / Clin. Cancer Res. by A Wallace (2008)
  10. Trowbridge, J.J., Xenocostas, A., Moon, R.T. & Bhatia, M. Glycogen synthase kinase-3 is an in vivo regulator of hematopoietic stem cell repopulation. Nat. Med. 12, 89–98 (2006). (10.1038/nm1339) / Nat. Med. by JJ Trowbridge (2006)
  11. Berger, C. et al. Safety and immunological effects of IL-15 administration in nonhuman primates. Blood 114, 2417–2426 (2009). (10.1182/blood-2008-12-189266) / Blood by C Berger (2009)
  12. Thompson, J.A. et al. Recombinant interleukin 2 toxicity, pharmacokinetics and immunomodulatory effects in a phase I trial. Cancer Res. 47, 4202–4207 (1987). / Cancer Res. by JA Thompson (1987)
  13. Treisman, J. et al. Interleukin-2–transduced lymphocytes grow in an autocrine fashion and remain responsive to antigen. Blood 85, 139–145 (1995). (10.1182/blood.V85.1.139.bloodjournal851139) / Blood by J Treisman (1995)
  14. Sahaf, B., Heydari, K., Herzenberg, L.A. & Herzenberg, L.A. Lymphocyte surface thiol levels. Proc. Natl. Acad. Sci. USA 100, 4001–4005 (2003). (10.1073/pnas.2628032100) / Proc. Natl. Acad. Sci. USA by B Sahaf (2003)
  15. Bernstein, I.D., Boyd, R.L. & van den Brink, M.R. Clinical strategies to enhance posttransplant immune reconstitution. Biol. Blood Marrow Transplant. 14, 94–99 (2008). (10.1016/j.bbmt.2007.10.003) / Biol. Blood Marrow Transplant. by ID Bernstein (2008)
  16. Jain, R.K. A new target for tumor therapy. N. Engl. J. Med. 360, 2669–2671 (2009). (10.1056/NEJMcibr0902054) / N. Engl. J. Med. by RK Jain (2009)
  17. Overwijk, W.W. et al. gp100/pmel 17 is a murine tumor rejection antigen: induction of 'self'-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med. 188, 277–286 (1998). (10.1084/jem.188.2.277) / J. Exp. Med. by WW Overwijk (1998)
  18. Rubinstein, M.P. et al. Converting IL-15 to a superagonist by binding to soluble IL-15Rα. Proc. Natl. Acad. Sci. USA 103, 9166–9171 (2006). (10.1073/pnas.0600240103) / Proc. Natl. Acad. Sci. USA by MP Rubinstein (2006)
  19. Lu, J. et al. Interleukin 15 promotes antigen-independent in vitro expansion and long-term survival of antitumor cytotoxic T lymphocytes. Clin. Cancer Res. 8, 3877–3884 (2002). / Clin. Cancer Res. by J Lu (2002)
  20. Gattinoni, L. et al. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat. Med. 15, 808–813 (2009). (10.1038/nm.1982) / Nat. Med. by L Gattinoni (2009)
  21. Dinauer, N. et al. Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T lymphocytes. Biomaterials 26, 5898–5906 (2005). (10.1016/j.biomaterials.2005.02.038) / Biomaterials by N Dinauer (2005)
  22. Davis, M.E., Chen, Z.G. & Shin, D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7, 771–782 (2008). (10.1038/nrd2614) / Nat. Rev. Drug Discov. by ME Davis (2008)
  23. Prescher, J.A., Dube, D.H. & Bertozzi, C.R. Chemical remodelling of cell surfaces in living animals. Nature 430, 873–877 (2004). (10.1038/nature02791) / Nature by JA Prescher (2004)
  24. Reddy, S.T. et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat. Biotechnol. 25, 1159–1164 (2007). (10.1038/nbt1332) / Nat. Biotechnol. by ST Reddy (2007)
  25. Woodrow, K.A. et al. Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat. Mater. 8, 526–533 (2009). (10.1038/nmat2444) / Nat. Mater. by KA Woodrow (2009)
  26. Bin Na, H., Song, I.C. & Hyeon, T. Inorganic nanoparticles for MRI contrast agents. Adv. Mater. 21, 2133–2148 (2009). (10.1002/adma.200802366) / Adv. Mater. by H Bin Na (2009)
  27. Tong, R. et al. Nanopolymeric therapeutics. MRS Bull. 34, 422–431 (2009). (10.1557/mrs2009.118) / MRS Bull. by R Tong (2009)
  28. Bartlett, D.W., Su, H., Hildebrandt, I.J., Weber, W.A. & Davis, M.E. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc. Natl. Acad. Sci. USA 104, 15549–15554 (2007). (10.1073/pnas.0707461104) / Proc. Natl. Acad. Sci. USA by DW Bartlett (2007)
  29. Weissleder, R., Kelly, K., Sun, E.Y., Shtatland, T. & Josephson, L. Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat. Biotechnol. 23, 1418–1423 (2005). (10.1038/nbt1159) / Nat. Biotechnol. by R Weissleder (2005)
  30. Dhar, S., Gu, F.X., Langer, R., Farokhzad, O.C. & Lippard, S.J. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc. Natl. Acad. Sci. USA 105, 17356–17361 (2008). (10.1073/pnas.0809154105) / Proc. Natl. Acad. Sci. USA by S Dhar (2008)
  31. Kirpotin, D.B. et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 66, 6732–6740 (2006). (10.1158/0008-5472.CAN-05-4199) / Cancer Res. by DB Kirpotin (2006)
  32. Reichardt, W. et al. Impact of mammalian target of rapamycin inhibition on lymphoid homing and tolerogenic function of nanoparticle-labeled dendritic cells following allogeneic hematopoietic cell transplantation. J. Immunol. 181, 4770–4779 (2008). (10.4049/jimmunol.181.7.4770) / J. Immunol. by W Reichardt (2008)
Dates
Type When
Created 15 years ago (Aug. 15, 2010, 2:30 p.m.)
Deposited 2 years, 3 months ago (May 18, 2023, 6:25 p.m.)
Indexed 41 minutes ago (Aug. 29, 2025, 1:16 p.m.)
Issued 15 years ago (Aug. 15, 2010)
Published 15 years ago (Aug. 15, 2010)
Published Online 15 years ago (Aug. 15, 2010)
Published Print 14 years, 11 months ago (Sept. 1, 2010)
Funders 0

None

@article{Stephan_2010, title={Therapeutic cell engineering with surface-conjugated synthetic nanoparticles}, volume={16}, ISSN={1546-170X}, url={http://dx.doi.org/10.1038/nm.2198}, DOI={10.1038/nm.2198}, number={9}, journal={Nature Medicine}, publisher={Springer Science and Business Media LLC}, author={Stephan, Matthias T and Moon, James J and Um, Soong Ho and Bershteyn, Anna and Irvine, Darrell J}, year={2010}, month=aug, pages={1035–1041} }